Clinical Development

Clinical Pipeline

KINASE INHIBITION

Sorafenib

Liver Cancer

Unresectable

Kidney Cancer

Advanced

Thyroid Cancer

Differentiated, DECISION – Monotherapy

Breast Cancer

RESILIENCE – Capecitabine +/-

Regorafenib 1

Metastatic COLORECTAL CANCER

CORRECT - Monotherapy

GIST

GRID - Monotherapy

LIVER CANCER

RESORCE - Second-line post Nexavar

COLORECTAL CANCER

Following Resection of Liver Metastases

PROTEASOME INHIBITION

Carfilzomib

Multiple Myeloma

Advanced myeloma, monotherapy
FOCUS – Relapsed and refractory, monotherapy vs. BAC2
ASPIRE – Relapsed, +/- lenalidomide/dexamethasone
ENDEAVOR-Relapsed, vs. bortezomib + dexamethasone
CLARION - Front-line, vs. bortezomib + melphalan + prednisone

Oprozomib

Hematologic Malignancies

Monotherapy
Combination Therapy - oprozomib, dexamethasone
Combination Therapy- oprozomib, lenalidomide, dexamethasone

Solid Tumor

Monotherapy

Palbociclib 3

Advanced breast cancer
1 Stivarga® (regorafenib) is a Bayer compound being developed by Bayer. Onyx receives a 20% royalty on all global net sales in approved markets. Bayer and Onyx are jointly promoting Stivarga in the U.S.
2 Best available care
3 Palbociclib is a Pfizer compound being developed by Pfizer. If approved, Onyx will receive an 8% royalty on  global net sales.